Oral Dimethyl Fumarate Targets HCA2-Expressing Skin Cells in the Imiquimod Mouse Model
- 18 February 2022
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2547-2550.e5
Abstract
No abstract availableFunding Information
- Deutsche Forschungsgemeinschaft (SCHW 416/10-1, SCHW 416/11-1)
This publication has 15 references indexed in Scilit:
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyNeurology, 2015
- Nuclear Heme Oxygenase-1 (HO-1) Modulates Subcellular Distribution and Activation of Nrf2, Impacting Metabolic and Anti-oxidant DefensesJournal of Biological Chemistry, 2014
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAEJournal of Clinical Investigation, 2014
- Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in miceJournal of Clinical Investigation, 2010
- Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patientsArchives of Dermatological Research, 2010
- The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonistBiochemical and Biophysical Research Communications, 2008
- Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)Cell Death & Differentiation, 2007
- Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in miceBlood, 2007
- Dimethylfumarate Induces Immunosuppression via Glutathione Depletion and Subsequent Induction of Heme Oxygenase 1Journal of Investigative Dermatology, 2007
- Langerhans cells renew in the skin throughout life under steady-state conditionsNature Immunology, 2002